Stifel resumed coverage of Janux Therapeutics (JANX) with a Buy rating and $45 price target The firm views the development of T cell engagers for solid tumor applications as a “relevant trend” within oncology. Janux’s TRACTr platform “meaningfully expands” the universe of targetable antigens, the analyst tells investors in a research note. Stifel expects a year-end update to improve visibility into the profile of JANX00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics initiated with a Buy at Guggenheim
- Piper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potential
- Janux Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations
- Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials